Roberto Alvarez-Lafuente

List of Publications by Year
in descending order

86 papers	2,432 citations	201674 27 h-index	233421 45 g-index
90 all docs	90 docs citations	90 times ranked	3102 citing authors

#	Article	IF	Citations
1	Short‐chain fatty acids during pregnancy in multiple sclerosis: A prospective cohort study. European Journal of Neurology, 2022, 29, 895-900.	3.3	5
2	Epstein-Barr Virus Load Correlates with Multiple Sclerosis-Associated Retrovirus Envelope Expression. Biomedicines, 2022, 10, 387.	3.2	7
3	High prevalence of intrathecal IgA synthesis in multiple sclerosis patients. Scientific Reports, 2022, 12, 4247.	3.3	1
4	Herpesvirus Antibodies, Vitamin D and Short-Chain Fatty Acids: Their Correlation with Cell Subsets in Multiple Sclerosis Patients and Healthy Controls. Cells, 2021, 10, 119.	4.1	12
5	Evolution of antibody titres against Epstein–Barr virus and human herpesvirus 6A/B and expression of multiple sclerosis-associated retrovirus in the serum of pregnant multiple sclerosis patients. Scientific Reports, 2021, 11, 8441.	3.3	0
6	Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple Sclerosis. Frontiers in Immunology, 2021, 12, 685139.	4.8	13
7	Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab. Frontiers in Immunology, 2021, 12, 760546.	4.8	3
8	Anti-Human Herpesvirus 6 A/B Antibodies Titers Correlate With Multiple Sclerosis-Associated Retrovirus Envelope Expression. Frontiers in Immunology, 2021, 12, 798003.	4.8	3
9	Soluble Receptor Isoform of IFN-Beta (sIFNAR2) in Multiple Sclerosis Patients and Their Association With the Clinical Response to IFN-Beta Treatment. Frontiers in Immunology, 2021, 12, 778204.	4.8	5
10	Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. Multiple Sclerosis Journal, 2020, 26, 912-923.	3.0	52
11	New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab. Frontiers in Neurology, 2020, 11, 579438.	2.4	9
12	MicroRNAs of Human Herpesvirus 6A and 6B in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients. Frontiers in Immunology, 2020, 11, 2142.	4.8	7
13	Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab. Scientific Reports, 2020, 10, 14244.	3.3	12
14	A Polymorphism Within the MBP Gene Is Associated With a Higher Relapse Number in Male Patients of Multiple Sclerosis. Frontiers in Immunology, 2020, 11, 771.	4.8	4
15	Syncytin‐1/HERV‐W envelope is an early activation marker of leukocytes and is upregulated in multiple sclerosis patients. European Journal of Immunology, 2020, 50, 685-694.	2.9	35
16	Serum antibodies to phosphatidylcholine in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e765.	6.0	10
17	Cytokine profile during pregnancy predicts relapses during pregnancy and postpartum in multiple sclerosis. Journal of the Neurological Sciences, 2020, 414, 116811.	0.6	7
18	Acetate correlates with disability and immune response in multiple sclerosis. PeerJ, 2020, 8, e10220.	2.0	23

#	Article	IF	Citations
19	Adaptive Features of Natural Killer Cells in Multiple Sclerosis. Frontiers in Immunology, 2019, 10, 2403.	4.8	17
20	Teriflunomide induces a tolerogenic bias in blood immune cells of MS patients. Annals of Clinical and Translational Neurology, 2019, 6, 355-363.	3.7	21
21	Neurofilament light chain levels in pregnant multiple sclerosis patients: a prospective cohort study. European Journal of Neurology, 2019, 26, 1200-1204.	3.3	17
22	Epidemiology of multiple sclerosis and vitamin D levels in Lanzarote, Canary Islands, Spain. PeerJ, 2019, 7, e8235.	2.0	4
23	Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain, 2018, 141, 1085-1093.	7.6	115
24	Low cytomegalovirus seroprevalence in early multiple sclerosis: a case for the â€˜hygiene hypothesisâ€™?. European Journal of Neurology, 2018, 25, 925-933.	3.3	26
25	Blood lymphocyte subsets identify optimal responders to IFN-beta in MS. Journal of Neurology, 2018, 265, 24-31.	3.6	11
26	Study of the possible link of 25â€hydroxyvitamin D with Epsteinâ€"Barr virus and human herpesvirus 6 in patients with multiple sclerosis. European Journal of Neurology, 2018, 25, 1446-1453.	3.3	16
27	New Life to an Old Treatment: Pegylated Interferon Beta 1a in the Management of Multiple Sclerosis. Current Medicinal Chemistry, 2018, 25, 3272-3283.	2.4	3
28	Metabolomic signatures associated with disease severity in multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e321.	6.0	89
29	Untreated relapsing remitting multiple sclerosis patients show antibody production against latent Epstein Barr Virus (EBV) antigens mainly in the periphery and innate immune IL-8 responses preferentially in the CNS. Journal of Neuroimmunology, 2017, 306, 40-45.	2.3	17
30	Study of the antiâ€‹scp›JCV‹/scp› antibody levels in a Spanish multiple sclerosis cohort. European Journal of Clinical Investigation, 2017, 47, 158-166.	3.4	14
31	Fingolimod Use for the Treatment of Multiple Sclerosis in a Clinical Practice Setting in Madrid. Clinical Neuropharmacology, 2017, 40, 29-33.	0.7	6
32	JC virus reactivation in patients with autoimmune rheumatic diseases treated with rituximab. Scandinavian Journal of Rheumatology, 2016, 45, 507-511.	1.1	5
33	Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients. European Journal of Neurology, 2016, 23, 182-189.	3.3	11
34	Adaptive natural killer cell response to cytomegalovirus and disability progression in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 741-752.	3.0	26
35	Clinical Data Associated With the Therapeutic Response to Glatiramer Acetate in Multiple Sclerosis Patients. Neuro - Open Journal, 2016, 3, 3-8.	0.1	0
36	Pharmacogenomic study in patients with multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e154.	6.0	19

#	Article	IF	Citations
37	Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. Annals of Neurology, 2015, 77, 447-457.	5.3	48
38	Multiple sclerosis retrovirus-like envelope gene: Role of the chromosome 20 insertion. BBA Clinical, 2015, 3, 162-167.	4.1	4
39	Identification of the major HHV-6 antigen recognized by cerebrospinal fluid IgG in multiple sclerosis. European Journal of Neurology, 2014, 21, 1096-1101.	3.3	25
40	Toll-like receptor-9 in Spanish multiple sclerosis patients: an association with the gender. European Journal of Neurology, 2014, 21, 537-540.	3.3	11
41	HERV-W polymorphism in chromosome X is associated with multiple sclerosis risk and with differential expression of MSRV. Retrovirology, 2014, 11, 2.	2.0	30
42	Classification of HHV-6A and HHV-6B as distinct viruses. Archives of Virology, 2014, 159, 863-870.	2.1	292
43	HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis. Journal of Medical Genetics, 2014, 51, 395-400.	3.2	19
44	Immunoglobulin M oligoclonal bands: Biomarker of targetable inflammation in primary progressive multiple sclerosis. Annals of Neurology, 2014, 76, 231-240.	5.3	51
45	Human Endogenous Retrovirus HERV-Fc1 Association with Multiple Sclerosis Susceptibility: A Meta-Analysis. PLoS ONE, 2014, 9, e90182.	2.5	29
46	Anti-Human Herpesvirus 6A/B IgG Correlates with Relapses and Progression in Multiple Sclerosis. PLoS ONE, 2014, 9, e104836.	2.5	36
47	Anti-JCV Antibodies Detection and JCV DNA Levels in PBMC, Serum and Urine in a Cohort of Spanish Multiple Sclerosis Patients Treated with Natalizumab. Journal of NeuroImmune Pharmacology, 2013, 8, 1277-1286.	4.1	19
48	Alternative splicing and proteolytic rupture contribute to the generation of soluble IL-6 receptors (sIL-6R) in rheumatoid arthritis. Cytokine, 2013, 61, 720-723.	3.2	19
49	Role of the Human Endogenous Retrovirus HERV-K18 in Autoimmune Disease Susceptibility: Study in the Spanish Population and Meta-Analysis. PLoS ONE, 2013, 8, e62090.	2.5	25
50	Expression of human endogenous retrovirus HERV-K18 is associated with clinical severity in osteoarthritis patients. Scandinavian Journal of Rheumatology, 2013, 42, 498-504.	1.1	8
51	Candidate Gene Study of TRAIL and TRAIL Receptors: Association with Response to Interferon Beta Therapy in Multiple Sclerosis Patients. PLoS ONE, 2013, 8, e62540.	2.5	18
52	The DNA Copy Number of Human Endogenous Retrovirus-W (MSRV-Type) Is Increased in Multiple Sclerosis Patients and Is Influenced by Gender and Disease Severity. PLoS ONE, 2013, 8, e53623.	2.5	64
53	MHC2TA mRNA levels and human herpesvirus 6 in multiple sclerosis patients treated with interferon beta along two-year follow-up. BMC Neurology, 2012, 12, 107.	1.8	14
54	Herpesvirus active replication in multiple sclerosis. Journal of the Neurological Sciences, 2011, 311, 98-102.	0.6	15

#	Article	IF	Citations
55	Human herpesvirus 6 and effectiveness of interferon beta 1b in multiple sclerosis patients. European Journal of Neurology, 2011, 18, 1027-1035.	3.3	27
56	Members 6B and 14 of the TNF receptor superfamily in multiple sclerosis predisposition. Genes and Immunity, 2011, 12, 145-148.	4.1	14
57	Validation of IRF5 as multiple sclerosis risk gene: putative role in interferon beta therapy and human herpes virus-6 infection. Genes and Immunity, 2011, 12, 40-45.	4.1	36
58	IL28B polymorphisms are not associated with the response to interferon-beta in multiple sclerosis. Journal of Neuroimmunology, 2011, 239, 101-104.	2.3	18
59	CD46 in a Spanish cohort of multiple sclerosis patients: genetics, mRNA expression and response to interferon-beta treatment. Multiple Sclerosis Journal, 2011, 17, 513-520.	3.0	19
60	TRAIL/TRAIL Receptor System and Susceptibility to Multiple Sclerosis. PLoS ONE, 2011, 6, e21766.	2.5	16
61	MHC2TA rs4774C and HHV‐6A active replication in multiple sclerosis patients. European Journal of Neurology, 2010, 17, 129-135.	3.3	29
62	Neutralizing antibodies, MxA expression and MMP‐9/TIMP‐1 ratio as markers of bioavailability of interferon‐beta treatment in multiple sclerosis patients: a two‐year follow‐up study. European Journal of Neurology, 2010, 17, 470-478.	3.3	14
63	Large-scale gene expression in bone marrow mesenchymal stem cells: a putative role for COL10A1 in osteoarthritis. Annals of the Rheumatic Diseases, 2010, 69, 1880-1885.	0.9	38
64	The ubiquitin‐proteasome pathway and viral infections in articular cartilage of patients with osteoarthritis. Rheumatology International, 2009, 29, 969-972.	3.0	8
65	CD46 expression and HHV-6 infection in patients with multiple sclerosis. Acta Neurologica Scandinavica, 2009, 120, 246-250.	2.1	10
66	Detection of human herpesvirus-6, Epstein-Barr virus and cytomegalovirus in formalin-fixed tissues from sudden infant death: A study with quantitative real-time PCR. Forensic Science International, 2008, 178, 106-111.	2.2	39
67	Herpesviruses and human endogenous retroviral sequences in the cerebrospinal fluid of multiple sclerosis patients. Multiple Sclerosis Journal, 2008, 14, 595-601.	3.0	67
68	Real-time polymerase chain reaction detection of Neisseria meningitidis in formalin-fixed tissues from sudden deaths. Diagnostic Microbiology and Infectious Disease, 2008, 60, 339-346.	1.8	12
69	Multicenter Comparison of PCR Assays for Detection of Human Herpesvirus 6 DNA in Serum. Journal of Clinical Microbiology, 2008, 46, 2700-2706.	3.9	73
70	Human herpesvirus-6 and multiple sclerosis: relapsing-remitting versus secondary progressive. Multiple Sclerosis Journal, 2007, 13, 578-583.	3.0	28
71	JC virus in cerebrospinal fluid samples of multiple sclerosis patients at the first demyelinating event. Multiple Sclerosis Journal, 2007, 13, 590-595.	3.0	30
72	Environment‐gene interaction in multiple sclerosis: Human herpesvirus 6 and MHC2TA. Human Immunology, 2007, 68, 685-689.	2.4	30

#	Article	IF	Citations
73	Interferon-beta treatment and active replication of the JC virus in relapsing-remitting multiple sclerosis patients. European Journal of Neurology, 2007, 14, 233-236.	3.3	13
74	Human parvovirus B19, varicella zoster virus, and human herpesvirus-6 in mesenchymal stem cells of patients with osteoarthritis: analysis with quantitative real-time polymerase chain reaction. Osteoarthritis and Cartilage, 2007, 15, 475-478.	1.3	30
75	Interferon beta treatment: Bioavailability and antiviral activity in multiple sclerosis patients. Journal of NeuroVirology, 2007, 13, 504-512.	2.1	8
76	Clinical parameters and HHV-6 active replication in relapsing–remitting multiple sclerosis patients. Journal of Clinical Virology, 2006, 37, S24-S26.	3.1	48
77	Human Herpesvirus 6 and Multiple Sclerosis: A One-Year Follow-up Study. Brain Pathology, 2006, 16, 20-27.	4.1	65
78	Virological analysis in the diagnosis of sudden children death: A medico-legal approach. Forensic Science International, 2006, 161, 8-14.	2.2	33
79	Potential relationship between herpes viruses and rheumatoid arthritis: analysis with quantitative real time polymerase chain reaction. Annals of the Rheumatic Diseases, 2005, 64, 1357-1359.	0.9	66
80	Human parvovirus B19, varicella zoster virus, and human herpes virus 6 in temporal artery biopsy specimens of patients with giant cell arteritis: analysis with quantitative real time polymerase chain reaction. Annals of the Rheumatic Diseases, 2005, 64, 780-782.	0.9	75
81	Beta-Interferon Treatment Reduces Human Herpesvirus-6 Viral Load in Multiple Sclerosis Relapses but Not in Remission. European Neurology, 2004, 52, 87-91.	1.4	24
82	Relapsing-Remitting Multiple Sclerosis and Human Herpesvirus 6 Active Infection. Archives of Neurology, 2004, 61, 1523.	4.5	102
83	Significance of nested PCR and quantitative real time PCR for cytomegalovirus detection in renal transplant recipients. International Journal of Antimicrobial Agents, 2004, 24, 455-462.	2.5	8
84	Active Human Herpesvirus 6 Infection in Patients With Multiple Sclerosis. Archives of Neurology, 2002, 59, 929.	4.5	69
85	Prevalence of herpesvirus DNA in MS patients and healthy blood donors. Acta Neurologica Scandinavica, 2002, 105, 95-99.	2.1	29
86	Serum IgM to Lipids Predicts the Response to Tysabri® and IFN-β in MS. SSRN Electronic Journal, 0, , .	0.4	0